Key result
Omapatrilat (40 mg/kg/d) and losartan (30 mg/kg/d) exerted cardioprotective properties beyond blood pressure lowering, preventing cardiomyocyte apoptosis and inhibiting extracellular matrix formation.
Why the study?
Does omapatrilat improve blood pressure and cardiac morphology compared to losartan, HCTZ, or their combination in spontaneously hypertensive rats on a high salt diet?
Does omapatrilat improve blood pressure and cardiac morphology compared to losartan, HCTZ, or their combination in spontaneously hypertensive rats on a high salt diet?
Answers are grounded in this paper and cite their sources.
Both vasopeptidase inhibition and AT1-receptor blockade exert cardioprotective properties beyond their blood pressure-lowering effects by preventing cardiomyocyte apoptosis and inhibiting extracellular matrix formation.
The aim of our study was to compare the cardioprotective effects of vasopeptidase inhibition with those of angiotensin type 1 (AT1)-receptor blockade, a diuretic and the combination of AT1-receptor blockade and a diuretic in an experimental rat model of essential hypertension on a high salt diet. Spontaneously hypertensive rats (SHR) (n =73) were divided into 6 groups to receive the following diet and drug regimens for 8 weeks: 1) low salt controls (NaCl 0.5%); 2) high salt controls (NaCl 6%); 3) omapatrilat (40 mg/kg/d) on a high salt diet; 4) losartan (30 mg/kg/d) on a high salt diet; 5) hydrochlorothiazide (HCTZ; 10 mg/kg/d) on a high salt diet; and 6) losartan+HCTZ (30+10 mg/kg/d) on a high salt diet. Blood pressure was measured by tail-cuff plethysmography. The histological score of myocardial damage, myocardial collagen volume fraction (CVF), connective tissue growth factor (CTGF) expression and cardiomyocyte apoptosis were determined. As an antihypertensive, omapatrilat showed greater efficacy than monotherapy with losartan or HCTZ, and was equally effective as the combination of losartan+HCTZ. Assessed by myocardial damage score, omapatrilat and losartan protected cardiac morphology better than HCTZ or the drug combination. Omapatrilat decreased CVF to a greater extent than the other therapies, whereas losartan was most effective in decreasing CTGF expression. All drug treatments, except HCTZ, decreased cardiomyocyte apoptosis. Our findings provide evidence that both vasopeptidase inhibition and AT1-receptor blockade exert cardioprotective properties beyond their blood pressure-lowering effects. Cardioprotection was associated with prevention of cardiomyocyte apoptosis and inhibition of extracellular matrix formation.
No takes yet. Share an insight, caveat, or question.
GRÖHOLM et al. (2004) studied Essential hypertension (n=73). Omapatrilat vs. Losartan, HCTZ, Losartan+HCTZ, low salt controls, high salt controls was evaluated on Blood pressure, myocardial damage score, myocardial collagen volume fraction, CTGF expression, and cardiomyocyte apoptosis. Omapatrilat (40 mg/kg/d) and losartan (30 mg/kg/d) exerted cardioprotective properties beyond blood pressure lowering, preventing cardiomyocyte apoptosis and inhibiting extracellular matrix formation.
Synapse has enriched 10 related papers. Consider them for comparative context: